DOCSLIB.ORG

Link Between Depression, Mortality Weakened

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Link Between Depression, Mortality Weakened 70 Psychosomatic Medicine C LINICAL P SYCHIATRY N EWS • February 2005 Link Between Depression, Mortality Weakened BY HEIDI SPLETE Rose, Ph.D., of Rush University Medical predicted a 21% increase in death from any guishing between clinical depression and Senior Writer Center, Chicago, and her colleagues (Psy- cause after age, race, and gender were ad- poor physical health can be difficult, the in- chosom. Med. 2004;66:823-30). justed for. However, no excess risk of mor- vestigators said. epressive symptoms are not inde- The investigators selected noninstitu- tality was associated with CES-D scores in Patients with scores in the highest quin- pendent predictors of mortality, tionalized adults aged 25 years and older a fully adjusted model that included de- tile on the CES-D had an 85% greater risk Daccording to data from a national who were participating in an ongoing, mographics, education, income, behav- of death from any cause, compared with sample of 3,617 adults. longitudinal study called Americans’ ioral risk factors, and three indicators of participants with the lowest CES-D scores, The findings of previous studies of as- Changing Lives. health status (hypertension, functional im- but no other quintiles showed an increased sociations between depressive symptoms A total of 542 deaths occurred during pairment, and life-threatening conditions). mortality risk, Dr. Everson-Rose and her and mortality have been inconsistent, and 7.5 years of follow-up. Each increase of 1 The physical complaints of patients associates reported. few of these studies have used population- standard unit on the Center for Epidemi- with depression often resemble symptoms Depressive symptoms were not signifi- based samples, said Susan A. Everson- ological Studies Depression scale (CES-D) of other health problems, and distin- cantly associated with mortality risk in a healthy subgroup of 2,833 adults (with 306 deaths) who reported good or excellent BRIEF SUMMARY. See package insert for full prescribing information. co-administering venlafaxine with other drugs affecting the serotonergic neurotransmitter systems, such as triptans, CONTRAINDICATIONS: Hypersensitivity to venlafaxine hydrochloride serotonin reuptake inhibitors, or lithium. Electroconvulsive Therapy (ECT):There are no clinical data establishing the benefit health at baseline. In addition, depressive or to any excipients in the formulation. Concomitant use in patients of ECT combined with Effexor XR treatment. Carcinogenesis, Mutagenesis, Impairment of Fertility—Carcinogenesis: taking monoamine oxidase inhibitors (MAOIs). WARNINGS: Potential There was no increase in tumors in mice and rats given up to 1.7 times the maximum recommended human dose (MRHD) for Interaction with MAOIs—Adverse reactions, some serious, have been reported in patients who recently on a mg/m2 basis. Mutagenesis:Venlafaxine and ODV were not mutagenic in the Ames reverse mutation assay in symptoms were not associated with in- discontinued an MAOI and started on venlafaxine, or who recently discontinued venlafaxine prior to initiation of an Salmonella bacteria or the CHO/HGPRT mammalian cell forward gene mutation assay. Venlafaxine was not clastogenic in MAOI. These reactions included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, hyperthermia several assays. ODV elicited a clastogenic response in the in vivo chromosomal aberration assay in rat bone marrow. creased mortality risk in patients without with features resembling neuroleptic malignant syndrome, seizures, and death. Effexor XR should not be used in Impairment of Fertility: No effects on reproduction or fertility in rats were noted at oral doses of up to 2 times the MRHD combination with an MAOI, or within at least 14 days of discontinuing treatment with an MAOI. At least 7 days on a mg/m2 basis. Pregnancy—Teratogenic Effects—Pregnancy Category C. Reproduction studies in rats given 2.5 functional impairments at baseline. should be allowed after stopping venlafaxine before starting an MAOI. Clinical Worsening and Suicide Risk—Adult times, and rabbits given 4 times the MRHD (mg/m2 basis) revealed no malformations in offspring. However, in rats given 2.5 and pediatric patients with major depressive disorder (MDD) may experience worsening of depression and/or emergence of times the MRHD, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during Although depressive symptoms were suicidal ideation and behavior (suicidality), whether or not taking antidepressants. This risk may persist until significant the first 5 days of lactation when dosing began during pregnancy and continued until weaning. There are no adequate and remission occurs. Although there has long been concern that antidepressants may induce worsening of depression and well-controlled studies in pregnant women; use Effexor XR during pregnancy only if clearly needed. Nonteratogenic Effects. associated with greater physical impair- emergence of suicidality, a causal role has not been established. Closely observe patients treated with antidepressants Neonates exposed to Effexor XR late in the third trimester have developed complications requiring prolonged hospitalization, for clinical worsening and suicidality, especially at the beginning of a course of drug therapy, or at the time of dose respiratory support, and tube feeding. Complications can arise immediately upon delivery. Reports include respiratory ment over time after demographics, so- increases or decreases. Consider changing the therapeutic regimen or discontinuing the medication in patients whose distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, MDD is persistently worse or whose emergent suicidality is severe, abrupt in onset, or not part of presenting symptoms. Due hyperreflexia, tremor, jitteriness, irritability, and constant crying. This is consistent with a direct toxic effect of SNRIs or a drug cioeconomic status, and baseline physical to possible comorbidity, when treating patients with other psychiatric and nonpsychiatric disorders, observe the same discontinuation syndrome. In some cases, it is consistent with serotonin syndrome. When treating a pregnant woman with precautions used when treating MDD patients. Anxiety, agitation, panic attacks, insomnia, irritability, hostility Effexor XR during the third trimester, carefully consider the potential risks and benefits of treatment and consider tapering impairment were controlled for, the CES- (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania, and mania have been reported in adults and Effexor XR in the third trimester. Labor, Delivery, Nursing—The effect on labor and delivery in humans is unknown. pediatrics treated with antidepressants for MDD and other psychiatric and nonpsychiatric indications. Although a causal link Venlafaxine and ODV have been reported to be excreted in human milk. Because of the potential for serious adverse reactions D does not measure clinical depression, between emergence of such symptoms and worsening of depression and/or emergence of suicidal impulses has not been in nursing infants from Effexor XR, a decision should be made whether to discontinue nursing or to discontinue the drug, established, consider changing the therapeutic regimen or discontinuing the medication in patients for whom such taking into account the importance of the drug to the mother. Pediatric Use—Effectiveness in pediatric patients has not which has been studied as a possible link symptoms are severe, abrupt in onset, or not part of presenting symptoms. Alert families and caregivers of patients been established (see WARNINGS-Clinical Worsening and Suicide Risk). No studies have adequately assessed the impact treated with antidepressants for MDD or other psychiatric or nonpsychiatric indications to monitor patients for of Effexor XR on growth, development, and maturation of children and adolescents. Studies suggest Effexor XR may adversely to mortality and cardiovascular health, emergence of agitation, irritability, and other symptoms described above, and emergence of suicidality, and to affect weight and height (see PRECAUTIONS-General, Changes in Height and Changes in Weight). Should the decision be report such symptoms immediately to health care providers. Write prescriptions for Effexor XR for the smallest quantity made to treat a pediatric patient with Effexor XR, regular monitoring of weight and height is recommended during treatment, ■ of capsules consistent with good patient management, to reduce risk of overdose. If it is decided to discontinue treatment, particularly if long term. The safety of Effexor XR for pediatric patients has not been assessed for chronic treatment >6 the investigators noted. medication should be tapered, as rapidly as feasible, but recognizing that abrupt discontinuation can be associated with months. In studies in patients aged 6-17, blood pressure and cholesterol increases considered to be clinically relevant were certain symptoms. Effexor XR is not approved for use in any indications in pediatrics. A major depressive episode may be similar to that observed in adult patients. The precautions for adults apply to pediatric patients. Geriatric Use—No overall the initial presentation of bipolar disorder. It is generally believed treating such an episode with an antidepressant alone may differences in effectiveness or safety were observed between geriatric and younger patients.
Load more

Recommended publications
  • Parosmia Due to COVID-19 Disease: a 268 Case Series
    Parosmia due to COVID-19 Disease: A 268 Case Series Rasheed Ali Rashid Tikrit University, College of Medicine, Department of Surgery/ Otolaryngology Ameer A. Alaqeedy University Of Anbar, College of Medicine, Department of Surgery/ Otolaryngology Raid M. Al-Ani ( [email protected] ) University Of Anbar, College of Medicine, Department of Surgery/Otolaryngology https://orcid.org/0000-0003-4263-9630 Research Article Keywords: Parosmia, COVID-19, Quality of life, Olfactory dysfunction, Case series Posted Date: May 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-506359/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Although parosmia is a common problem in the era of the COVID-19 pandemic, few studies assessed the demographic and clinical aspects of this debilitating symptom. We aimed to evaluate the socio-clinical characteristics and outcome of various options of treatment of individuals with parosmia due to COVID- 19 infection. The study was conducted at two main Hospitals in the Ramadi and Tikrit cities, Iraq, on patients with a chief complaint of parosmia due to COVID-19 disease. The study involved 7 months (August 2020-February 2021). Detailed demographic and clinical characteristics and treatment options with their outcome were recorded and analyzed. Out of 268 patients with parosmia, there were 197 (73.5%) females. The majority were from age group ≤ 30 years (n = 188, 70.1%), housewives (n = 150, 56%), non-smokers (n = 222, 82.8%), and associated with dysgeusia (n = 207, 77.2%) but not associated with nasal symptoms (n = 266, 99.3%).
    [Show full text]
  • Taste and Smell Disorders in Clinical Neurology
    TASTE AND SMELL DISORDERS IN CLINICAL NEUROLOGY OUTLINE A. Anatomy and Physiology of the Taste and Smell System B. Quantifying Chemosensory Disturbances C. Common Neurological and Medical Disorders causing Primary Smell Impairment with Secondary Loss of Food Flavors a. Post Traumatic Anosmia b. Medications (prescribed & over the counter) c. Alcohol Abuse d. Neurodegenerative Disorders e. Multiple Sclerosis f. Migraine g. Chronic Medical Disorders (liver and kidney disease, thyroid deficiency, Diabetes). D. Common Neurological and Medical Disorders Causing a Primary Taste disorder with usually Normal Olfactory Function. a. Medications (prescribed and over the counter), b. Toxins (smoking and Radiation Treatments) c. Chronic medical Disorders ( Liver and Kidney Disease, Hypothyroidism, GERD, Diabetes,) d. Neurological Disorders( Bell’s Palsy, Stroke, MS,) e. Intubation during an emergency or for general anesthesia. E. Abnormal Smells and Tastes (Dysosmia and Dysgeusia): Diagnosis and Treatment F. Morbidity of Smell and Taste Impairment. G. Treatment of Smell and Taste Impairment (Education, Counseling ,Changes in Food Preparation) H. Role of Smell Testing in the Diagnosis of Neurodegenerative Disorders 1 BACKGROUND Disorders of taste and smell play a very important role in many neurological conditions such as; head trauma, facial and trigeminal nerve impairment, and many neurodegenerative disorders such as Alzheimer’s, Parkinson Disorders, Lewy Body Disease and Frontal Temporal Dementia. Impaired smell and taste impairs quality of life such as loss of food enjoyment, weight loss or weight gain, decreased appetite and safety concerns such as inability to smell smoke, gas, spoiled food and one’s body odor. Dysosmia and Dysgeusia are very unpleasant disorders that often accompany smell and taste impairments.
    [Show full text]
  • Smell Distortions: Prevalence, Longevity and Impact of Parosmia in a Population-Based, Longitudinal Study Spanning 10 Years
    Smell distortions: Prevalence, longevity and impact of parosmia in a population-based, longitudinal study spanning 10 years Jonas K. Olofsson*1, Fredrik Ekesten1, & Steven Nordin2 1Department of Psychology, Stockholm University, Stockholm, Sweden 2Department of Psychology, Umeå University, Umeå, Sweden *Corresponding author: [email protected] Abstract. Parosmia, experiences of distorted smell sensations, is a common consequence of covid-19. The phenomenon is not well understood in terms of its impact and long-term outcomes. We examined parosmia in a population-based sample from the Betula study that was conducted in Umeå in northern Sweden (baseline data collected in 1998-2000). We used a baseline sample of 2168 individuals aged 35-90 years and with no cognitive impairment at baseline. We investigated the prevalence of parosmia and, using regression analyses, its relationship to other olfactory and cognitive variables and quality of life. Benefitting from the longitudinal study design, we also assessed the persistence of parosmia over 5 and 10 years prospectively. Parosmia was prevalent in 5% of the population (n=104) and was often co- occurring with phantosmia (“olfactory hallucinations”), but was not associated with lower self-rated overall quality of life or poor performance on olfactory or cognitive tests. For some individuals, parosmia was retained 5 years (17%) or even 10 years later (10%). Thus, parosmia is relative common in the population, and can be persistent for some individuals. This work provides rare insights into the expected impact of, and recovery from parosmia, with implications for those suffering from qualitative olfactory dysfunction following covid-19. 2 Introduction Parosmia is an olfactory disorder (OD) where odor perception is distorted and different stimuli trigger unpleasant odor sensations previously not associated with the stimuli (i.e.
    [Show full text]
  • Sixty Seconds on . . . Parosmia
    NEWS The BMJ BMJ: first published as 10.1136/bmj.m4332 on 9 November 2020. Downloaded from Cite this as: BMJ 2020;371:m4332 Sixty seconds on . parosmia http://dx.doi.org/10.1136/bmj.m4332 Abi Rimmer Published: 09 November 2020 I’ve heard of anosmia but what's this? The charity Fifth Sense explains that parosmia is the medical term for distortions of the sense of smell. Someone with parosmia may be able to detect odours, but the smell of certain things—or sometimes everything—is different, and often unpleasant.1 Such as? Jennifer Spicer, a US based infectious diseases doctor, said that following her recovery from covid-19, coffee, wine, and other foods tasted like gasoline.2 Nicola Watt, who also recovered from the virus, described similar symptoms to the Times.3 “Quite suddenly everything smelt and tasted like a horrid rubbish bin,” Watt said. Sounds awful. Is this from covid-19? Not specifically. Parosmia is common with all types of post-viral smell loss, and over half of people who have lost their sense of smell because of a virus will go on to experience it.4 Fragrance writer Louise Woollam, for example, suffered from parosmia after a cold and found that most foods tasted of sewage or mud and most things smelt disgusting.5 How awful! Yes, and what’s worse Woollam, like many other people, experienced phantosmia as well when “phantom” smells appear in the absence of any odour. These can manifest as “normal” smells – for example, being able to smell garlic when there is no garlic present – but they can also be unpleasant.1 Is there a cure? Unfortunately not.
    [Show full text]
  • Clinical Diagnosis and Treatment of Olfactory Dysfunction
    Clinical Diagnosis and Treatment of Olfactory Dysfunction Seok Hyun Cho Hanyang Med Rev 2014;34:107-115 http://dx.doi.org/10.7599/hmr.2014.34.3.107 Department of Otorhinolaryngology-Head and Neck Surgery, Hanyang University College of Medicine, Seoul, Korea pISSN 1738-429X eISSN 2234-4446 Olfactory dysfunction is a relatively common disorder that is often under-recognized by Correspondence to: Seok Hyun Cho Department of Otorhinolaryngology-Head both patients and clinicians. It occurs more frequently in older ages and men, and decreases and Neck Surgery, Hanyang University patients’ quality of life, as olfactory dysfunction may affect the emotion and memory func- Hospital, 222 Wangsimni-ro, Seongdong-gu, tions. Three main causes of olfactory dysfunction are sinonasal diseases, upper respiratory Seoul 133-792, Korea Tel: +82-2-2290-8583 viral infection, and head trauma. Olfactory dysfunction is classified quantitatively (hypos- Fax: +82-2-2293-3335 mia and anosmia) and qualitatively (parosmia and phantosmia). From a pathophysiologi- E-mail: [email protected] cal perspective, olfactory dysfunction is also classified by conductive or sensorineural types. All patients with olfactory dysfunction will need a complete history and physical examina- Received 17 April 2014 Revised 23 June 2014 tion to identify any possible or underlying causes and psychophysical olfactory tests are Accepted 3 July 2014 essential to estimate the residual olfactory function, which is the most important prognos- This is an Open Access article distributed under tic factor. CT or MRI may be adjunctively used in some indicated cases such as head trauma the terms of the Creative Commons Attribution and neurodegenerative disorders.
    [Show full text]
  • Will My Patient Attempt Suicide Again?
    Will my patient attempt suicide again? Risk factors help you identify patients who need immediate hospitalization for safety ® Dowden Health Media s. J, age 32, comes to our mental health clinic seeking treatment for depression and anxi- Mety. She reportsCopyright she has attemptedFor personal suicide use only 3 times. Ms. J describes the first 2 attempts—both of which occurred when she was in her 20s after the end of a relationship—as “cries for attention” that were rela- tively innocuous. Her third suicide attempt, however, was an acetaminophen overdose approximately 1 year ago that resulted in hospitalization and irreversible liver damage. VEER Ms. J acknowledges that over the last several weeks / she has been thinking about suicide almost constantly, HAMELS especially as the anniversary of her fiancé’s death ap- proaches. She says she has a nearly full bottle of zolpi- LAURENT © dem in her medicine cabinet and fantasizes about taking all of them and just “going to sleep.” Elizabeth L. Jeglic, PhD Associate professor Department of psychology Many patients—especially those with depression—ex- John Jay College of Criminal Justice perience recurrent thoughts of death or a wish to die, New York, NY but only about 10% attempt suicide.1 To identify those who are at highest risk and warrant hospitalization, it is vital to assess how a history of suicidal behavior and other factors impact the risk for future suicide at- tempts. This article: • examines research on patients who have attempted suicide and risk factors for repeat suicide attempts • describes characteristics of patients with multiple attempts • explores the link between a history of self-injurious Current Psychiatry behavior and suicide attempts.
    [Show full text]
  • Can Clinical Staging of Primary Amoebic Meningoencephalitis Be of Any Therapeutic Benefit Abdul Mannan Baig Dr
    eCommons@AKU Department of Biological & Biomedical Sciences Medical College, Pakistan January 2017 Can clinical staging of primary amoebic meningoencephalitis be of any therapeutic benefit Abdul Mannan Baig Dr. Aga Khan University, [email protected] Armaghan-e-Rehman Mansoor [email protected] Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_bbs Recommended Citation Baig, A. M., Mansoor, A. (2017). Can clinical staging of primary amoebic meningoencephalitis be of any therapeutic benefit. EC MICROBIOLOGY, 5(3), 101-108. Available at: http://ecommons.aku.edu/pakistan_fhs_mc_bbs/300 Cronicon OPEN ACCESS EC MICROBIOLOGY Review Article Can Clinical Staging of Primary Amoebic Meningoencephalitis be of any Therapeutic Benefit? Abdul Mannan Baig* and Armaghan-e-Rehman Mansoor The Aga Khan University, Karachi, Pakistan *Corresponding Author: The Department of BBS, Aga Khan University, Medical College, Karachi, Pakistan. Received: December 15, 2016; Published: January 19, 2017 Summary Naegleria fowleri, is a free-living amoeba (FLA) known to infect humans and cause a fatal disease called primary amoebic menin- goencephalitis (PAM). All of the patients are commonly admitted to the emergency room (ER). Often, treatment in the ER is delayed due to the rarity of disease leading to a delay in the diagnosis and late arrival of patients to the ER. The attempts to reduce raised intracranial pressure and subsequent herniation of the brain stem are challenging and become the cause of death in the affected patients during their stay in ER. Use of drugs like mannitol to reduce raised intra-cerebral pressure (ICP) could prove dangerous in the presence of cerebral haemorrhage and this fact could be overlooked during the management of patients with PAM.
    [Show full text]
  • PAROXETINE TABLETS, USP 10 Mg, 20 Mg, 30 Mg and 40 Mg Rx Only
    PAROXETINE- paroxetine hydrochloride tablet, film coated REMEDYREPACK INC. ---------- PAROXETINE TABLETS, USP 10 mg, 20 mg, 30 mg and 40 mg Rx only Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of paroxetine tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Paroxetine tablets are not approved for use in pediatric patients (see WARNINGS, Clinical Worsening and Suicide Risk, PRECAUTIONS, Information for Patients, and PRECAUTIONS, Pediatric Use). DESCRIPTION Paroxetine hydrochloride is an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans-4 R-(4'-fluorophenyl)-3 S-[(3',4'- methylenedioxyphenoxy) methyl] piperidine hydrochloride anhydrous and has the empirical formula of C 19H 20FNO 3•HCl . The molecular weight is 365.8 (anhydrous) (329.4 as free base).
    [Show full text]
  • Topamax® Tablets and Sprinkle Capsules Topiramate New Zealand Data Sheet
    TOPAMAX® TABLETS AND SPRINKLE CAPSULES TOPIRAMATE NEW ZEALAND DATA SHEET 1. PRODUCT NAME TOPAMAX® 25 mg, 50 mg, 100 mg & 200 mg film-coated tablets TOPAMAX® Sprinkle 15 mg, 25 mg & 50 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION TABLETS Each tablet contains 25 mg, 50 mg, 100 mg or 200 mg of topiramate. Excipient(s) with known effect: Lactose monohydrate For a full list of excipients, see section 6.1. SPRINKLE CAPSULES Each capsule contains 15 mg, 25 mg or 50 mg of topiramate. Excipients with known effect: Sugar For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM TABLETS 25 mg: Round, white, film-coated tablets, marked “TOP” on one side and “25” on the other. 50 mg: Round, light-yellow, film-coated tablets, marked “TOP” on one side and “50” on the other 100 mg: Round, yellow, film-coated tablets, marked “TOP” on one side and “100” on the other 200 mg: Round, salmon, film-coated tablets, marked “TOP” on one side and “200” on the other. SPRINKLE CAPSULES Hard capsules enclosing small, white to off-white spheres. Each gelatin capsule consists of a clear (natural) capsule cap and a white capsule body. 15 mg: imprinted with “TOP” on cap and “15 mg” on body 25 mg: imprinted with “TOP” on cap and “25 mg” on body 50mg: imprinted with “TOP” on cap and “50mg” on body (not marketed). CCDS201005v23 1 TOPAMAX(201215)ADS 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS EPILEPSY TOPAMAX is indicated in adults and children, 2 years and over: • as monotherapy in patients with newly diagnosed epilepsy • for conversion to monotherapy in patients with epilepsy • as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome.
    [Show full text]
  • REMERON/Remeronsoltab with Caution These Highlights Do Not Include All the Information Needed to Use in Patients with Risk Factors for QT Prolongation
    HIGHLIGHTS OF PRESCRIBING INFORMATION QT Prolongation: Use REMERON/REMERONSolTab with caution These highlights do not include all the information needed to use in patients with risk factors for QT prolongation. (5.5, 7) REMERON/REMERONSolTab safely and effectively. See full Increased Appetite/Weight Gain: REMERON/REMERONSolTab prescribing information for REMERON/REMERONSolTab. has been associated with increased appetite and weight gain. (5.6) ® REMERON (mirtazapine) tablets, for oral use Somnolence: May impair judgment, thinking and/or motor skills. ® REMERONSolTab (mirtazapine) orally disintegrating tablets Use with caution when engaging in activities requiring alertness, Initial U.S. Approval: 1996 such as driving or operating machinery. (5.7, 7) Activation of Mania/Hypomania: Screen patients for bipolar WARNING: SUICIDAL THOUGHTS AND BEHAVIORS disorder prior to initiating treatment. (2.3, 5.8) See full prescribing information for complete boxed warning. Seizures: Use with caution in patients with a seizure disorder. (5.9) Increased risk of suicidal thoughts and behavior in pediatric and Elevated Cholesterol/Triglycerides: Has been reported with young adult patients taking antidepressants. Closely monitor all REMERON use. (5.10) antidepressant-treated patients for clinical worsening and Hyponatremia: May occur as a result of treatment with emergence of suicidal thoughts and behaviors. serotonergic antidepressants, including REMERON/REMERONSolTab is not approved for use in pediatric REMERON/REMERONSolTab. (5.11) patients. (5.1,
    [Show full text]
  • Anosmia, Parosmia and the Impact of Long Covid-19
    medRxiv preprint doi: https://doi.org/10.1101/2020.11.26.20239152; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Altered Smell and Taste: anosmia, parosmia and the impact of long Covid-19 Dr Duika L Burges Watson (Altered Eating Research Network, Faculty of Medical Sciences, Newcastle University, UK) Dr Miglena Campbell (Altered Eating Research Network, Centre for Applied Psychological Science, Teesside University, UK) Professor Claire Hopkins (Professor of Rhinology, King’s College, London, UK) Professor Barry Smith (Director of the Institute of Philosophy, University of London, UK) Chris Kelly (AbScent, UK) Professor Vincent Deary (Altered Eating Research Network, Psychology, Northumbria University, UK) Abstract Background: Qualitative olfactory (smell) dysfunctions are a common side effect of post- viral illness and known to impact on quality of life and health status. Evidence is emerging that taste and smell loss are common symptoms of Covid-19 that may emerge and persist long after initial infection. The aim of the present study was to document the impact of post Covid-19 alterations to taste and smell. Methods: We conducted passive and active thematic analysis of user-generated text from 9000 users of the AbScent Covid-19 Smell and Taste Loss moderated Facebook support group from March 24 to 30th September 2020. Results: Participants reported difficulty understanding, explaining and managing altered taste and smell; a lack of interpersonal and professional explanation or support; altered eating; appetite loss, weight change; loss of pleasure in food, eating and social engagement; altered intimacy and an altered relationship to self and others.
    [Show full text]
  • Self-Reported Olfactory and Gustatory Dysfunction in Patients with COVID-19 Infection*
    ORIGINAL CONTRIBUTION Self-reported olfactory and gustatory dysfunction in patients with COVID-19 infection* 1 1 2 D. Kooper , H.Coerts , H. Mkadmi Rhinology Online, Vol 4: 140 - 146, 2021 http://doi.org/10.4193/RHINOL/20.088 1 Department of Otorhinolaryngology, Reinier de Graaf Gasthuis, Delft, The Netherlands 2 Department of Medical Research, Reinier de Graaf Gasthuis, Delft, The Netherlands *Received for publication: December 4, 2020 Accepted: August 11, 2021 Published: August 17, 2021 Abstract Objective: To investigate the incidence, comorbidity and recovery period of smell and taste loss in patients with COVID-19 infec- tion, who were treated as outpatient or admitted to the hospital. Methods: 103 patients with COVID-19 infection were recruited from a COVID-19 Test Centre (CTC) and hospital wards. Subjects fil- led in an online self-report survey retrospectively at least six months after recruitment. The following epidemiological and clinical outcomes have been studied: age, gender, comorbidities, general and otolaryngological symptoms and recovery of the olfactory or gustatory loss. Results: All patients suffered from mild to severe respiratory disease. A high frequency of smell and taste dysfunctions was reported (71.2% and 78.9% respectively). 33% of the patients reported anosmia and 33% reported ageusia. The most frequent symptoms were fever, loss of smell and taste, dyspnoea and headache. The most common comorbidities were hypertension, obesity and diabetes. Males suffered 2.6 times more often from olfactory dysfunction than females. No statistical difference with regard to recovery time were found between man and women. There was a significant difference in the sense of taste scores before COVID-19 infection and during COVID-19 infection.
    [Show full text]